Line Gutte Borgwardt (L Borgwardt, Line Borgwardt)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 4

Top Topics

Signaling Pathway

Intellectual Disability

Patient Reported Outcomes

Top Venues

Journal of assisted reproduction and genetics

The Journal of experimental medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Christopher James Arthur Duncan, Morten Kelder Skouboe, Sophie Howarth, Anne Kruse Hollensen, Rui Chen, Malene Landbo Børresen, Benjamin J Thompson, Jarmila Stremenova Spegarova, Catherine F Hatton, Frederik Filip Stæger, Mette K Andersen, John Whittaker, Soren Riis Paludan, Sofie Eg Jørgensen, Martin K Thomsen, Jacob Giehm Mikkelsen, Carsten Heilmann, Daniela Buhas, Nina F Øbro, Jakob Thaning Bay, Hanne Vibeke Hansen Marquart, M Teresa de la Morena, Joseph A Klejka, Matthew Hirschfeld, Line Gutte Borgwardt, Isabel Forss, Tania Nicole Masmas, Anja Poulsen, Francisco Noya, Guy A Rouleau, Torben Hansen, Sirui Zhou, Anders Albrechtsen, Reza Alizadehfar, Eric J Allenspach, Sophie Hambleton, Trine Hyrup Mogensen
Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. The Journal of experimental medicine 219 (6) (2022)
Line Gutte Borgwardt, Ferdinando Ceravolo, Giulia Zardi, Andrea Ballabeni, Allan Meldgaard Lund
Relationship between MAN2B1 genotype/subcellular localization subgroups, antidrug antibody detection, and long-term velmanase alfa treatment outcomes in patients with alpha-mannosidosis. JIMD reports 64 (2) (2022)
Line Gutte Borgwardt, Ferdinando Ceravolo, Giulia Zardi, Andrea Ballabeni, Allan Meldgaard Lund
Relationship between MAN2B1 genotype/subcellular localization subgroups, antidrug antibody detection, and long-term velmanase alfa treatment outcomes in patients with alpha-mannosidosis. JIMD reports 64 (2) (2022)
Line Gutte Borgwardt, K W Olsen, M Rossing, R Borup Helweg-Larsen, M Toftager, A Pinborg, J Bogstad, K Løssl, A Zedeler, M L Grøndahl
Rare genetic variants suggest dysregulation of signaling pathways in low- and high-risk patients developing severe ovarian hyperstimulation syndrome. Journal of assisted reproduction and genetics 37 (11) (2020)